Inhibitory receptors as targets for cancer immunotherapy

European Journal of Immunology

Volumn 45, Issue 7, 2015, Pages 1892-1905

  Turnis, Meghan E ^a   Andrews, Lawrence P ^b   Vignali, Dario A A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; CTLA4; Inhibitory receptors; LAG3; PD1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROTEIN DERIVATIVE; CD223 ANTIGEN; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; LYMPHOCYTE ACTIVATION GENE 3; MARKER GENE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84935432896     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344413     Document Type: Review

References (147)

1. Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R. et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009. 10: 29-37.
2. Baitsch, L., Legat, A., Barba, L., Fuertes Marraco, S. A., Rivals, J. P., Baumgaertner, P., Christiansen-Jucht, C. et al., Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012. 7: e30852.
3. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
4. Shevach, E. M., Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009. 30: 636-645.
5. Couzin-Frankel, J., Breakthrough of the year 2013. Cancer immunotherapy. Science 2013. 342: 1432-1433.
6. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D. et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012. 366: 2443-2454.
7. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G. et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012. 366: 2455-2465.
8. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C. et al., Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 2010. 107: 7875-7880.
9. Pardoll, D. M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012. 12: 252-264.
10. Baldo, B. A., Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2013. 2: e26333.
11. Moran, A. E., Kovacsovics-Bankowski, M. and Weinberg, A. D., The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 2013. 25: 230-237.
12. Kao, J., Ko, E. C., Eisenstein, S., Sikora, A. G., Fu, S. and Chen, S. H., Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 2011. 77: 12-19.
13. Kalos, M. and June, C. H., Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013. 39: 49-60.
14. Palucka, K. and Banchereau, J., Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013. 39: 38-48.
15. Murakami, N. and Riella, L. V., Co-inhibitory pathways and their importance in immune regulation. Transplantation 2014. 98: 3-14.
16. Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B. et al., Reversal of the TCR stop signal by CTLA-4. Science 2006. 313: 1972-1975.
17. Lu, Y., Schneider, H. and Rudd, C. E., Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood 2012. 120: 4560-4570.
18. Oderup, C., Cederbom, L., Makowska, A., Cilio, C. M. and Ivars, F., Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 2006. 118: 240-249.
19. Onishi, Y., Fehervari, Z., Yamaguchi, T. and Sakaguchi, S., Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 2008. 105: 10113-10118.
20. Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J. et al., Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011. 332: 600-603.
21. Leach, D. R., Krummel, M. F. and Allison, J. P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996. 271: 1734-1736.
22. Ledford, H., Melanoma drug wins US approval. Nature 2011. 471: 561.
23. Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C. et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013. 210: 1695-1710.
24. Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., Garbe, C. et al., Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013. 31: 616-622.
25. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010. 363: 711-723.
26. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C. et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011. 364: 2517-2526.
27. Addeo, A. and Rinaldi, C. R., Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient. Case Rep. Oncol. 2013. 6: 285-288.
28. Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D. et al., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015. 33: 1889-1894.
29. Della Vittoria Scarpati, G., Fusciello, C., Perri, F., Sabbatino, F., Ferrone, S., Carlomagno, C. and Pepe, S., Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco. Targets Ther. 2014. 7: 203-209.
30. Barnes, M. J., Griseri, T., Johnson, A. M., Young, W., Powrie, F. and Izcue, A., CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal. Immunol. 2013. 6: 324-334.
31. Mancardi, D. A., Iannascoli, B., Hoos, S., England, P., Daeron, M. and Bruhns, P., FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J. Clin. Invest. 2008. 118: 3738-3750.
32. Furness, A. J., Vargas, F. A., Peggs, K. S. and Quezada, S. A., Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014. 35: 290-298.
33. Keler, T., Halk, E., Vitale, L., O'Neill, T., Blanset, D., Lee, S., Srinivasan, M. et al., Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 2003. 171: 6251-6259.
34. Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M. et al., A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 2011. 9: 204.
35. Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. and Allison, J. P., Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 2013. 210: 1389-1402.
36. Keir, M. E., Butte, M. J., Freeman, G. J. and Sharpe, A. H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008. 26: 677-704.
37. Wherry, E. J., Ha, S. J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S. et al., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007. 27: 670-684.
38. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. and Freeman, G. J., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007. 27: 111-122.
39. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T. et al., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010. 116: 1757-1766.
40. Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T. et al., Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007. 104: 3360-3365.
41. Maine, C. J., Aziz, N. H., Chatterjee, J., Hayford, C., Brewig, N., Whilding, L., George, A. J. et al., Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 2014. 63: 215-224.
42. Muenst, S., Schaerli, A. R., Gao, F., Daster, S., Trella, E., Droeser, R. A., Muraro, M. G. et al., Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2014. 146: 15-24.
43. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C. et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002. 8: 793-800.
44. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. and Riley, J. L., SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004. 173: 945-954.
45. Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T. et al., Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002. 169: 5538-5545.
46. Poole, R. M., Pembrolizumab: first global approval. Drugs 2014. 74: 1973-1981.
47. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D. et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013. 369: 134-144.
48. Garon, E. B., Leighl, N. B., Rizvi, N. A., Blumenschein, G. R., Balmanoukian, A. S., Eder, J. P., Goldman, J. W. et al., Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014. 32: 8020.
49. Seiwert, T. Y., Burtness, B., Weiss, J., Gluck, I., Eder, J. P., Pai, S. I., Dolled-Filhart, M. et al., A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meeting Abstracts 2014. 32: 6011.
50. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A. et al., Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015.
51. Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R. et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014. 32: 1020-1030.
52. Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J. et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015. 372: 311-319.
53. Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J. et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014. 515: 558-562.
54. Johnson, D. B., Rioth, M. J. and Horn, L., Immune checkpoint inhibitors in NSCLC. Curr. Treat. Options Oncol. 2014. 15: 658-669.
55. Cho, D. C., Sosman, J. A., Sznol, M., Gordon, M. S., Hollebecque, A., Hamid, O., McDermott, D. F. et al., Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2013. 31: 4505.
56. Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y. and Schlom, J., Antibody dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. Cancer Immunol. Res. 2015.
57. Daud, A. I., Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proc. Ann. Meeting AACR. 2014. CT104.
58. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002. 99: 12293-12297.
59. Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y. et al., IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 2015. 112: 1501-1509.
60. Saloura, V., Zuo, Z., Koeppen, H., Keck, M. K., Khattri, A., Boe, M., Hegde, P. S. et al., Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. ASCO Meeting Abstracts 2014. 32: 6009.
61. Patel, S. P. and Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 2015. 14: 847-856.
62. Huang, C. T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L. et al., Role of LAG-3 in regulatory T cells. Immunity 2004. 21: 503-513.
63. Huard, B., Gaulard, P., Faure, F., Hercend, T. and Triebel, F., Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994. 39: 213-217.
64. Workman, C. J., Rice, D. S., Dugger, K. J., Kurschner, C. and Vignali, D. A., Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur. J. Immunol. 2002. 32: 2255-2263.
65. Workman, C. J., Wang, Y., El Kasmi, K. C., Pardoll, D. M., Murray, P. J., Drake, C. G. and Vignali, D. A., LAG-3 regulates plasmacytoid dendritic cell homeostasis. J. Immunol. 2009. 182: 1885-1891.
66. Workman, C. J., Cauley, L. S., Kim, I. J., Blackman, M. A., Woodland, D. L. and Vignali, D. A., Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 2004. 172: 5450-5455.
67. Workman, C. J. and Vignali, D. A., Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J. Immunol. 2005. 174: 688-695.
68. Workman, C. J., Dugger, K. J. and Vignali, D. A., Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J. Immunol. 2002. 169: 5392-5395.
69. Li, N., Wang, Y., Forbes, K., Vignali, K. M., Heale, B. S., Saftig, P., Hartmann, D. et al., Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 2007. 26: 494-504.
70. Li, N., Workman, C. J., Martin, S. M. and Vignali, D. A., Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J. Immunol. 2004. 173: 6806-6812.
71. Woo, S. R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L. et al., Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012. 72: 917-927.
72. Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R. et al., PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014. 124: 2246-2259.
73. Curran, M. A., Montalvo, W., Yagita, H. and Allison, J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010. 107: 4275-4280.
74. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H. et al., Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013. 369: 122-133.
75. Callahan, M., Horak, C., Curran, M., Hollman, T., Schaer, D., Yuan, J., Lesokhin, A. et al., Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J. Immunother. Cancer 2013. 1: O6.
76. Sznol, M., Kluger, H. M., Callahan, M. K., Postow, M. A., Gordon, R. A., Segal, N. H., Rizvi, N. A. et al., Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO Meeting Abstracts 2014. 32: LBA9003.
77. Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T., Harrison, M. R., Vaishampayan, U. N. et al., Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. ASCO Meeting Abstracts 2014. 32: 5009.
78. Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L. et al., Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 2013. 36: 382-389.
79. van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J., van der Sluis, T. M., Gall, H. E. et al., Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012. 13: 509-517.
80. Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P. et al., Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014. 312: 1744-1753.
81. Xu, Y., Hunt, N. H. and Bao, S., The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res. 2008. 18: 1220-1229.
82. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R. et al., Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994. 264: 713-716.
83. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A. et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014. 371: 2189-2199.
84. Snyder Charen, A., Makarov, V., Merghoub, T., Walsh, L., Yuan, J., Miller, M., Kannan, K. et al., The neoantigen landscape underlying clinical response to ipilimumab. ASCO Meeting Abstracts 2014. 32: 3003.
85. Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W. et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015. 348: 124-128.
86. Schirrmacher, V. and Fournier, P., Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 2009. 542: 565-605.
87. Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T. et al., Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 2014. 6: 226ra232.
88. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S. et al., Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002. 415: 536-541.
89. Gautron, A. S., Dominguez-Villar, M., deMarcken, M. and Hafler, D. A., Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur. J. Immunol. 2014. 44: 2703-2711.
90. Anderson, A. C., Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2014. 2: 393-398.
91. Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M. et al., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010. 207: 2175-2186.
92. Yang, Z. Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E. et al., IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 2012. 122: 1271-1282.
93. Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J. et al., TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012. 7: e30676.
94. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K. and Anderson, A. C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010. 207: 2187-2194.
95. Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J. et al., Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011. 117: 4501-4510.
96. Huang, Y. H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K. et al., CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2014. 517: 386-390.
97. da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I. et al., Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2014. 2: 410-422.
98. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y. et al., Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012. 13: 832-842.
99. Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B. et al., Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000. 290: 1768-1771.
100. Rygiel, T. P. and Meyaard, L., CD200R signaling in tumor tolerance and inflammation: a tricky balance. Curr. Opin. Immunol. 2012. 24: 233-238.
101. Adhikary, G., Grun, D., Kerr, C., Balasubramanian, S., Rorke, E. A., Vemuri, M., Boucher, S. et al., Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation. PLoS One 2013. 8: e84324.
102. Kawasaki, B. T., Mistree, T., Hurt, E. M., Kalathur, M. and Farrar, W. L., Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 2007. 364: 778-782.
103. Coles, S. J., Wang, E. C., Man, S., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L., CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011. 25: 792-799.
104. Pillai, V., Pozdnyakova, O., Charest, K., Li, B., Shahsafaei, A. and Dorfman, D. M., CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders. Am. J. Clin. Pathol. 2013. 140: 536-543.
105. Wright, G. J., Cherwinski, H., Foster-Cuevas, M., Brooke, G., Puklavec, M. J., Bigler, M., Song, Y. et al., Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 2003. 171: 3034-3046.
106. Gorczynski, R. M., Chen, Z., Khatri, I., Podnos, A. and Yu, K., Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res. Treat. 2013. 142: 271-282.
107. Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S. et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014. 26: 923-937.
108. Yu, X., Harden, K., Gonzalez, L. C., Francesco, M., Chiang, E., Irving, B., Tom, I. et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 2009. 10: 48-57.
109. Stanietsky, N., Rovis, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J. et al., Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur. J. Immunol. 2013. 43: 2138-2150.
110. Lozano, E., Dominguez-Villar, M., Kuchroo, V. and Hafler, D. A., The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 2012. 188: 3869-3875.
111. Chauvin, J. M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M. et al., TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest. 2015. 125: 2046-2058.
112. Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J. et al., Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 2014. 40: 569-581.
113. Joller, N., Hafler, J. P., Brynedal, B., Kassam, N., Spoerl, S., Levin, S. D., Sharpe, A. H. et al., Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 2011. 186: 1338-1342.
114. Derre, L., Rivals, J. P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O. et al., BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 2010. 120: 157-167.
115. Pasero, C., Speiser, D. E., Derre, L. and Olive, D., The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr. Opin. Pharmacol. 2012. 12: 478-485.
116. M'Hidi, H., Thibult, M. L., Chetaille, B., Rey, F., Bouadallah, R., Nicollas, R., Olive, D. et al., High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am. J. Clin. Pathol. 2009. 132: 589-596.
117. Morel, Y., Schiano de Colella, J. M., Harrop, J., Deen, K. C., Holmes, S. D., Wattam, T. A., Khandekar, S. S. et al., Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 2000. 165: 4397-4404.
118. Krieg, C., Boyman, O., Fu, Y. X. and Kaye, J., B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat. Immunol. 2007. 8: 162-171.
119. Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M. et al., CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012. 72: 887-896.
120. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W. et al., gp100/pmel 17 is a murine tumor rejection antigen: induction of self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 1998. 188: 277-286.
121. Hobo, W., Norde, W. J., Schaap, N., Fredrix, H., Maas, F., Schellens, K., Falkenburg, J. H. et al., B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J. Immunol. 2012. 189: 39-49.
122. Cai, G., Anumanthan, A., Brown, J. A., Greenfield, E. A., Zhu, B. and Freeman, G. J., CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 2008. 9: 176-185.
123. Farren, T. W., Giustiniani, J., Liu, F. T., Tsitsikas, D. A., Macey, M. G., Cavenagh, J. D., Oakervee, H. E. et al., Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood 2011. 118: 2174-2183.
124. Lasaro, M. O., Sazanovich, M., Giles-Davis, W., Mrass, P., Bunte, R. M., Sewell, D. A., Hussain, S. F. et al., Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol. Ther. 2011. 19: 1727-1736.
125. Greaves, P. and Gribben, J. G., The role of B7 family molecules in hematologic malignancy. Blood 2013. 121: 734-744.
126. Hashiguchi, M., Kobori, H., Ritprajak, P., Kamimura, Y., Kozono, H. and Azuma, M., Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. USA 2008. 105: 10495-10500.
127. Wang, L., Kang, F. B. and Shan, B. E., B7-H3-mediated tumor immunology: friend or foe? Int. J. Cancer 2014. 134: 2764-2771.
128. Kraan, J., van den Broek, P., Verhoef, C., Grunhagen, D. J., Taal, W., Gratama, J. W. and Sleijfer, S., Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br. J. Cancer 2014. 111: 149-156.
129. Sun, J., Mao, Y., Zhang, Y. Q., Guo, Y. D., Mu, C. Y., Fu, F. Q. and Zhang, X. G., Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer. Oncol. Lett. 2013. 6: 1253-1260.
130. Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L. et al., Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 2010. 97: 409-418.
131. Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S. et al., Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 2012. 18: 3834-3845.
132. Sica, G. L., Choi, I. H., Zhu, G., Tamada, K., Wang, S. D., Tamura, H., Chapoval, A. I. et al., B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003. 18: 849-861.
133. Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M. et al., B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006. 203: 871-881.
134. He, C., Qiao, H., Jiang, H. and Sun, X., The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin. Dev. Immunol. 2011. 2011: 695834.
135. Jiang, J., Zhu, Y., Wu, C., Shen, Y., Wei, W., Chen, L., Zheng, X. et al., Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 2010. 59: 1707-1714.
136. Liu, W., Shibata, K., Koya, Y., Kajiyama, H., Senga, T., Yamashita, M. and Kikkawa, F., B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol. Clin. Oncol. 2014. 2: 219-225.
137. Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. and Seliger, B., B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 2011. 17: 3100-3111.
138. Chen, C., Zhu, Y. B., Shen, Y., Zhu, Y. H., Zhang, X. G. and Huang, J. A., Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas. J. Immunother. 2012. 35: 354-358.
139. Chen, L. J., Sun, J., Wu, H. Y., Zhou, S. M., Tan, Y., Tan, M., Shan, B. E. et al., B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 2011. 60: 1047-1055.
140. Dangaj, D., Lanitis, E., Zhao, A., Joshi, S., Cheng, Y., Sandaltzopoulos, R., Ra, H. J. et al., Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 2013. 73: 4820-4829.
141. Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L. F. et al., VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011. 208: 577-592.
142. Zhu, Y., Yao, S., Iliopoulou, B. P., Han, X., Augustine, M. M., Xu, H., Phennicie, R. T. et al., B7-H5 costimulates human T cells via CD28H. Nat. Commun. 2013. 4: 2043.
143. Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S. et al., VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014. 74: 1924-1932.
144. LeMercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J. et al., VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014. 74: 1933-1944.
145. Vela, M., Aris, M., Llorente, M., Garcia-Sanz, J. A. and Kremer, L., Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol. 2015. 6: 12.
146. Galon, J., Pages, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I. et al., Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 2012. 10: 205.
147. Galon, J., Angell, H. K., Bedognetti, D. and Marincola, F. M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013. 39: 11-26.